Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.61 |
| ▸ | LMNA | P02545 | 5/20 | 0.61 |
| ▸ | HPGD | P15428 | 4/20 | 0.61 |
| ▸ | GLA | P06280 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.60 |
| ▸ | RAB9A | P51151 | 4/20 | 0.60 |
| ▸ | NPC1 | O15118 | 4/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15905318 | 1.00 | ALDH1A1 (0.61) | ALDH1A1LMNAHPGDGLASMN1; SMN2 | |
| SCHEMBL15899385 | 0.84 | ALDH1A1 (0.62) | ALDH1A1LMNAHPGDGLASMN1; SMN2 | |
| SCHEMBL15899383 | 0.84 | ALDH1A1 (0.62) | ALDH1A1LMNAHPGDGLASMN1; SMN2 | |
| SCHEMBL15903179 | 0.80 | ALDH1A1 (0.51) | ALDH1A1LMNAHPGDGLASMN1; SMN2 | |
| SCHEMBL17320382 | 0.80 | ALDH1A1 (0.51) | ALDH1A1LMNAHPGDGLASMN1; SMN2 | |
| SCHEMBL13373265 | 0.75 | ALDH1A1 (0.49) | ALDH1A1LMNAHPGDGLASMN1; SMN2 | |
| SCHEMBL21284942 | 0.73 | ALDH1A1 (0.47) | ALDH1A1LMNAHPGDGLASMN1; SMN2 | |
| SCHEMBL31566 | 0.72 | ADH1B (0.61) | ALDH1A1LMNAHPGDGLASMN1; SMN2 | |
| SCHEMBL15904635 | 0.72 | KMT2A (0.53) | ALDH1A1LMNAHPGDSMN1; SMN2RAB9A | |
| SCHEMBL17320381 | 0.72 | KMT2A (0.53) | ALDH1A1LMNAHPGDSMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9376387-B2 | Oxidisable pyridine derivatives, their preparation and use as anti-alzheimer agents | INSA INST NAT DES SCIENCES APPLIQUEES DE ROUEN (FR) | 2016-06-28 | — | — | US | disclosed |
| US-9376387-B2 | Oxidisable pyridine derivatives, their preparation and use as anti-alzheimer agents | INSA INST NAT DES SCIENCES APPLIQUEES DE ROUEN (FR) | 2016-06-28 | — | — | US | disclosed |
| US-20150353493-A1 | OXIDISABLE PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE AS ANTI-ALZHEIMER AGENTS | INSA (INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE ROUEN (FR) | 2015-12-10 | — | — | US | disclosed |
| US-20150353493-A1 | OXIDISABLE PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE AS ANTI-ALZHEIMER AGENTS | INSA (INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE ROUEN (FR) | 2015-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353493-A1 | OXIDISABLE PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE AS ANTI-ALZHEIMER AGENTS | CBR3, CBR1, CYB5R3 | ALDH1A1 3811/4885LMNA 2012/4885HPGD 755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.